Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 18, 2025 11:54 ET | Source: NeuExcell Therapeutics

NeuExcell Therapeutics Reports Encouraging Clinical Results with World’s First In Situ Conversion Therapy for Malignant Glioma

NeuExcell’s NXL-004, first in situ conversion gene therapy, shows promising safety and efficacy in 11 GBM patients at ESMO Asia 2025